- Home
- LESL vs IMUX Comparison
LESL vs IMUX Comparison
Compare LESL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- IMUX
- Stock Information
- Founded
- LESL 1963
- IMUX 2016
- Country
- LESL United States
- IMUX United States
- Employees
- LESL N/A
- IMUX N/A
- Industry
- LESL Diversified Commercial Services
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- LESL Miscellaneous
- IMUX Health Care
- Exchange
- LESL Nasdaq
- IMUX Nasdaq
- Market Cap
- LESL 66.9M
- IMUX 67.8M
- IPO Year
- LESL 2020
- IMUX N/A
- Fundamental
- Price
- LESL $0.36
- IMUX $0.93
- Analyst Decision
- LESL Hold
- IMUX Strong Buy
- Analyst Count
- LESL 9
- IMUX 5
- Target Price
- LESL $1.71
- IMUX $7.50
- AVG Volume (30 Days)
- LESL 4.5M
- IMUX 1.1M
- Earning Date
- LESL 08-06-2025
- IMUX 08-11-2025
- Dividend Yield
- LESL N/A
- IMUX N/A
- EPS Growth
- LESL N/A
- IMUX N/A
- EPS
- LESL N/A
- IMUX N/A
- Revenue
- LESL $1,319,859,000.00
- IMUX N/A
- Revenue This Year
- LESL $1.42
- IMUX N/A
- Revenue Next Year
- LESL $2.67
- IMUX N/A
- P/E Ratio
- LESL N/A
- IMUX N/A
- Revenue Growth
- LESL N/A
- IMUX N/A
- 52 Week Low
- LESL $0.35
- IMUX $0.56
- 52 Week High
- LESL $3.63
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- LESL 38.21
- IMUX 52.26
- Support Level
- LESL $0.40
- IMUX $0.94
- Resistance Level
- LESL $0.68
- IMUX $1.18
- Average True Range (ATR)
- LESL 0.06
- IMUX 0.08
- MACD
- LESL -0.00
- IMUX -0.00
- Stochastic Oscillator
- LESL 3.20
- IMUX 30.97
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.